Cargando…
Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases
BACKGROUND: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by APEX technology and direct Sanger sequencing of known genes. However, these meth...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352121/ https://www.ncbi.nlm.nih.gov/pubmed/22277662 http://dx.doi.org/10.1186/1750-1172-7-8 |
_version_ | 1782232851455934464 |
---|---|
author | Audo, Isabelle Bujakowska, Kinga M Léveillard, Thierry Mohand-Saïd, Saddek Lancelot, Marie-Elise Germain, Aurore Antonio, Aline Michiels, Christelle Saraiva, Jean-Paul Letexier, Mélanie Sahel, José-Alain Bhattacharya, Shomi S Zeitz, Christina |
author_facet | Audo, Isabelle Bujakowska, Kinga M Léveillard, Thierry Mohand-Saïd, Saddek Lancelot, Marie-Elise Germain, Aurore Antonio, Aline Michiels, Christelle Saraiva, Jean-Paul Letexier, Mélanie Sahel, José-Alain Bhattacharya, Shomi S Zeitz, Christina |
author_sort | Audo, Isabelle |
collection | PubMed |
description | BACKGROUND: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by APEX technology and direct Sanger sequencing of known genes. However, these methods are time consuming, expensive and unable to provide a result if the patient carries a new gene mutation. In addition, multiplicity of phenotypes associated with the same gene defect may be overlooked. METHODS: To overcome these challenges, we designed an exon sequencing array to target 254 known and candidate genes using Agilent capture. Subsequently, 20 DNA samples from 17 different families, including four patients with known mutations were sequenced using Illumina Genome Analyzer IIx next-generation-sequencing (NGS) platform. Different filtering approaches were applied to identify the genetic defect. The most likely disease causing variants were analyzed by Sanger sequencing. Co-segregation and sequencing analysis of control samples validated the pathogenicity of the observed variants. RESULTS: The phenotype of the patients included retinitis pigmentosa, congenital stationary night blindness, Best disease, early-onset cone dystrophy and Stargardt disease. In three of four control samples with known genotypes NGS detected the expected mutations. Three known and five novel mutations were identified in NR2E3, PRPF3, EYS, PRPF8, CRB1, TRPM1 and CACNA1F. One of the control samples with a known genotype belongs to a family with two clinical phenotypes (Best and CSNB), where a novel mutation was identified for CSNB. In six families the disease associated mutations were not found, indicating that novel gene defects remain to be identified. CONCLUSIONS: In summary, this unbiased and time-efficient NGS approach allowed mutation detection in 75% of control cases and in 57% of test cases. Furthermore, it has the possibility of associating known gene defects with novel phenotypes and mode of inheritance. |
format | Online Article Text |
id | pubmed-3352121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33521212012-05-16 Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases Audo, Isabelle Bujakowska, Kinga M Léveillard, Thierry Mohand-Saïd, Saddek Lancelot, Marie-Elise Germain, Aurore Antonio, Aline Michiels, Christelle Saraiva, Jean-Paul Letexier, Mélanie Sahel, José-Alain Bhattacharya, Shomi S Zeitz, Christina Orphanet J Rare Dis Research BACKGROUND: Inherited retinal disorders are clinically and genetically heterogeneous with more than 150 gene defects accounting for the diversity of disease phenotypes. So far, mutation detection was mainly performed by APEX technology and direct Sanger sequencing of known genes. However, these methods are time consuming, expensive and unable to provide a result if the patient carries a new gene mutation. In addition, multiplicity of phenotypes associated with the same gene defect may be overlooked. METHODS: To overcome these challenges, we designed an exon sequencing array to target 254 known and candidate genes using Agilent capture. Subsequently, 20 DNA samples from 17 different families, including four patients with known mutations were sequenced using Illumina Genome Analyzer IIx next-generation-sequencing (NGS) platform. Different filtering approaches were applied to identify the genetic defect. The most likely disease causing variants were analyzed by Sanger sequencing. Co-segregation and sequencing analysis of control samples validated the pathogenicity of the observed variants. RESULTS: The phenotype of the patients included retinitis pigmentosa, congenital stationary night blindness, Best disease, early-onset cone dystrophy and Stargardt disease. In three of four control samples with known genotypes NGS detected the expected mutations. Three known and five novel mutations were identified in NR2E3, PRPF3, EYS, PRPF8, CRB1, TRPM1 and CACNA1F. One of the control samples with a known genotype belongs to a family with two clinical phenotypes (Best and CSNB), where a novel mutation was identified for CSNB. In six families the disease associated mutations were not found, indicating that novel gene defects remain to be identified. CONCLUSIONS: In summary, this unbiased and time-efficient NGS approach allowed mutation detection in 75% of control cases and in 57% of test cases. Furthermore, it has the possibility of associating known gene defects with novel phenotypes and mode of inheritance. BioMed Central 2012-01-25 /pmc/articles/PMC3352121/ /pubmed/22277662 http://dx.doi.org/10.1186/1750-1172-7-8 Text en Copyright ©2012 Audo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Audo, Isabelle Bujakowska, Kinga M Léveillard, Thierry Mohand-Saïd, Saddek Lancelot, Marie-Elise Germain, Aurore Antonio, Aline Michiels, Christelle Saraiva, Jean-Paul Letexier, Mélanie Sahel, José-Alain Bhattacharya, Shomi S Zeitz, Christina Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases |
title | Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases |
title_full | Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases |
title_fullStr | Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases |
title_full_unstemmed | Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases |
title_short | Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases |
title_sort | development and application of a next-generation-sequencing (ngs) approach to detect known and novel gene defects underlying retinal diseases |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352121/ https://www.ncbi.nlm.nih.gov/pubmed/22277662 http://dx.doi.org/10.1186/1750-1172-7-8 |
work_keys_str_mv | AT audoisabelle developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT bujakowskakingam developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT leveillardthierry developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT mohandsaidsaddek developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT lancelotmarieelise developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT germainaurore developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT antonioaline developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT michielschristelle developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT saraivajeanpaul developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT letexiermelanie developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT saheljosealain developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT bhattacharyashomis developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases AT zeitzchristina developmentandapplicationofanextgenerationsequencingngsapproachtodetectknownandnovelgenedefectsunderlyingretinaldiseases |